TY  - JOUR
AU  - Ruhnke, Leo
AU  - Bill, Marius
AU  - Zukunft, Sven
AU  - Eckardt, Jan-Niklas
AU  - Schäfer, Silvia
AU  - Stasik, Sebastian
AU  - Hanoun, Maher
AU  - Schroeder, Thomas
AU  - Fransecky, Lars
AU  - Steffen, Björn
AU  - Krause, Stefan W
AU  - Scholl, Sebastian
AU  - Hochhaus, Andreas
AU  - Sauer, Tim
AU  - Kraus, Sabrina
AU  - Schäfer-Eckart, Kerstin
AU  - Kaufmann, Martin
AU  - Jost, Edgar
AU  - Brümmendorf, Tim
AU  - Schliemann, Christoph
AU  - Mikesch, Jan-Henrik
AU  - Krug, Utz
AU  - Hänel, Mathias
AU  - Morgner, Anke
AU  - Schaich, Markus
AU  - Neubauer, Andreas
AU  - Repp, Roland
AU  - Niemann, Dirk
AU  - Seggewiss-Bernhardt, Ruth
AU  - Meinhardt, Achim
AU  - Kullmer, Johannes
AU  - Kaiser, Ulrich
AU  - Blau, Wolfgang
AU  - Kiani, Alexander
AU  - Grigoleit, Götz Ulrich
AU  - Giagounidis, Aristoteles
AU  - Wurm, Alexander Arthur
AU  - Altmann, Heidi
AU  - Middeke, Jan Moritz
AU  - Schetelig, Johannes
AU  - Müller-Tidow, Carsten
AU  - Stölzel, Friedrich
AU  - Baldus, Claudia D
AU  - Platzbecker, Uwe
AU  - Serve, Hubert
AU  - Bornhäuser, Martin
AU  - Thiede, Christian
AU  - Röllig, Christoph
TI  - Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.
JO  - Blood advances
VL  - 9
IS  - 6
SN  - 2473-9529
CY  - Washington, DC
PB  - American Society of Hematology
M1  - DKFZ-2025-00674
SP  - 1392 - 1404
PY  - 2025
AB  - In 2022, the European LeukemiaNet (ELN) risk stratification for patients with acute myeloid leukemia (AML) has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) by evaluating 1570 patients with newly diagnosed AML (median age, 56 years) treated with cytarabine-based intensive chemotherapy regimens. Compared with 2017 ELN classification (ELN17), which allocated 595 (38
KW  - Humans
KW  - Leukemia, Myeloid, Acute: diagnosis
KW  - Leukemia, Myeloid, Acute: therapy
KW  - Leukemia, Myeloid, Acute: mortality
KW  - Middle Aged
KW  - Male
KW  - Adult
KW  - Female
KW  - Aged
KW  - Prognosis
KW  - Risk Assessment
KW  - Young Adult
KW  - Europe
KW  - Aged, 80 and over
KW  - Adolescent
KW  - Antineoplastic Combined Chemotherapy Protocols: therapeutic use
LB  - PUB:(DE-HGF)16
C6  - pmid:39504561
DO  - DOI:10.1182/bloodadvances.2024013304
UR  - https://inrepo02.dkfz.de/record/300197
ER  -